Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Secondary solid tumors after allogeneic hematopoietic SCT in Japan

Abstract

To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age- and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Gallagher G, Forrest DL . Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007; 109: 84–92.

    Article  PubMed  Google Scholar 

  2. Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.

    Article  CAS  PubMed  Google Scholar 

  3. Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation: late effects working party of the European cooperative group for blood and marrow transplantation and the European late effect project group. Ann Intern Med 1999; 131: 738–744.

    Article  CAS  PubMed  Google Scholar 

  4. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.

    Article  CAS  PubMed  Google Scholar 

  5. Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115–121.

    Article  CAS  PubMed  Google Scholar 

  6. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T . Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008; 38: 641–648.

    Article  PubMed  Google Scholar 

  7. Vandenbroucke J . A shortcut method for calculating the 95% percent confidence interval of the standardized mortality ratio. Am J Epidemiol 1982; 115: 303–304.

    Article  Google Scholar 

  8. Esteve J, Benhamou E, Raymond L . Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ 1994; 128: 1–302.

    Google Scholar 

  9. Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1140–1154.

    Article  Google Scholar 

  10. Lin DY . Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16: 901–910.

    Article  CAS  PubMed  Google Scholar 

  11. Baker KS, DeFor TE, Burns JK, Ramsay NK, Neglia JP, Robison LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  PubMed  Google Scholar 

  12. Deeg HJ, Socie G . Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833–1844.

    CAS  PubMed  Google Scholar 

  13. Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME et al. Impact of chronic GvHD therapy on the development of squamous cell cancers after hematopoietic stem cell transplantation: an international case–control study. Blood 2005; 105: 3802–3811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141–1150.

    Article  CAS  PubMed  Google Scholar 

  15. Winter P, Schoeneich G, Miersch WD, Klehr HU . Tumour induction as a consequence of immunosuppression after renal transplantation. Int Urol Nephrol 1997; 29: 701–709.

    Article  CAS  PubMed  Google Scholar 

  16. Faber P, Fisch P, Waterhouse M, Schmitt-Gräff A, Bertz H, Finke J et al. Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. Blood 2006; 107: 3389–3396.

    Article  CAS  PubMed  Google Scholar 

  17. Hasegawa W, Pond GR, Rifkind JT, Messner HA, Lau A, Daly AS et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 35: 51–55.

    Article  CAS  PubMed  Google Scholar 

  18. Leisenring W, Friedman DL, Flowers MED, Schwartz JL, Deeg HJ . Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119–1126.

    Article  PubMed  Google Scholar 

  19. Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.

    Article  CAS  PubMed  Google Scholar 

  20. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789.

    Article  CAS  PubMed  Google Scholar 

  21. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms, following bone marrow transplantation. Blood 1996; 87: 3633–3639.

    CAS  PubMed  Google Scholar 

  22. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K . Studies of mortality of atomic bomb survivors. Report 13. Solid cancer and noncancer disease mortality. 1950-1997. Radiat Res 2003; 160: 381–407.

    Article  CAS  PubMed  Google Scholar 

  23. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996; 334: 745–751.

    Article  CAS  PubMed  Google Scholar 

  24. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487–497.

    Article  CAS  PubMed  Google Scholar 

  25. Charles M . UNSCEAR report 2000: sources and effects of ionizing radiation. United Nations Scientific Comittee on the effects of atomic radiation. J Radiol Prot 2001; 21: 83–86.

    Article  CAS  PubMed  Google Scholar 

  26. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330–1336.

    Article  CAS  PubMed  Google Scholar 

  27. Cohen A, Rovelli A, van Lint MT, Merlo F, Gaiero A, Mulas R et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant 2001; 28: 1125–1128.

    Article  CAS  PubMed  Google Scholar 

  28. Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 270–278.

    Article  CAS  PubMed  Google Scholar 

  29. Tucker MA, D’Angio GJ, Boice Jr JD, Strong LC, Li FP, Stovall M et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588–593.

    Article  CAS  PubMed  Google Scholar 

  30. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625–3632.

    CAS  PubMed  Google Scholar 

  31. Favre-Schmuziger G, Hofer S, Passweg J, Tichelli A, Hoffmann T, Speck B et al. Treatment of solid tumors following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 895–898.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to A Yokota.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokota, A., Ozawa, S., Masanori, T. et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 47, 95–100 (2012). https://doi.org/10.1038/bmt.2011.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.23

Keywords

This article is cited by

Search

Quick links